Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia - the HOMI-LUNG Project - Hospital-Acquired-Pneumonia

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The HOMI-LUNG - HAP study is part of the HOMI-LUNG project, funded by the Horizon Europe program. The HOMI-LUNG project is an international, interdisciplinary project that aims to better understand the causal links between respiratory tract infections (i.e. pneumonia) and the progression of cardiovascular disease. More specifically, the project aims to quantify the burden of cardiovascular disease after pneumonia and assess patients\' acceptability of long-term health alterations, as well as to define pneumonia endotypes with distinct pathobiological mechanisms associated with exacerbation of cardiovascular disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 80
Healthy Volunteers: f
View:

⁃ Group A (patients with acute cardiac disease)

• Male or female

• Age ≥ 40years old

• Hospitalized for acute coronary syndrome for less than 7 days.

• Informed consent from the patient

• Person insured under a health insurance scheme

⁃ Group B (patients with chronic cardiovascular disease)

• Male or female,

• Age ≥ 40 years old

• Undergoing coronary artery by-pass surgery

• Hospitalized in intensive care unit for \> 12 hours

• Informed consent from the patient

• Person insured under a health insurance scheme

⁃ Group C (patients at risk of CVRD without chronic cardiovascular disease)

• Male or female,

• Age ≥ 40 years old

• Familial high levels of cholesterol or triglycerides

• With no personal history of CVRD, with a recent negative cardiac exercise test (last test inferior to 12 months)

• Follow-up for lipid abnormalities at high risk of CVRD events

• Informed consent from the patient

• Person insured under a health insurance scheme

⁃ Group D (patients with HAP)

• Male or female

• Age ≥ 40years old

• With one or more risk factors for CVD among:

⁃ smoking, abnormal lipidic levels, high blood pressure, obesity, diabetes mellitus, chronic kidney disease

• Cured from mechanically ventilated HAP during the current hospitalization

• Informed consent from the patient or relatives

• Person insured under a health insurance scheme

Locations
Other Locations
France
Angers University Hospital
NOT_YET_RECRUITING
Angers
Nantes University Hospital
RECRUITING
Nantes
Rennes University Hospital
NOT_YET_RECRUITING
Rennes
Rouen University Hospital
NOT_YET_RECRUITING
Rouen
Toulouse University Hospital
NOT_YET_RECRUITING
Toulouse
Contact Information
Primary
Antoine ROQUILLY
Antoine.roquilly@univ-nantes.fr
+33253482840
Time Frame
Start Date: 2025-01-02
Estimated Completion Date: 2029-05-01
Participants
Target number of participants: 300
Treatments
Other: Group A : Patients with acute major cardiovascular event
Comparator
Other: Group B: Patients with severe chronic cardiovascular disease
Comparator
Other: Group C: Patients with a high risk of CVD, yet no known history of CVRD or HA
Comparator
Experimental: Group D: Patients cured of HAP
Related Therapeutic Areas
Sponsors
Leads: Nantes University Hospital

This content was sourced from clinicaltrials.gov